Huang Guohang, Cai Lili, Guo Jinlin, Zhu Ruyi, Zhu Lina
Department of Pharmacy, The Third People's Hospital of Cangnan County, Wenzhou, 325804, Zhejiang Province, China.
Department of Pharmacy, Shanxi Provincial People's Hospital, Taiyuan, 030012, Shanxi, China.
Eur J Clin Microbiol Infect Dis. 2025 Jun 12. doi: 10.1007/s10096-025-05184-8.
The administration of antibiotics can induce gut microbiota dysbiosis leading to Clostridium difficile infection and has been linked to conditions such as irritable bowel syndrome and metabolic syndrome. However, the specific effects of different antibiotics on the gut microbiota composition remain poorly characterized, particularly in human studies. A previous published phase I study explored the role of a colon-targeted adsorbent DAV132 to mitigate the effects of antibiotics-related dysbiosis on the gut microbiota in healthy individuals. Using the publicly available dataset from this publication PRJNA922086, we evaluated the impacts of a 5-day intravenous treatment with two broad-spectrum beta-lactam/beta-lactamase inhibitor antibiotics ceftazidime-avibactam, piperacillin-tazobactam and a third-generation cephalosporin ceftriaxone on the diversity, composition, and bacterial interactions at days 1, 6, and 37 post-administration. All three antibiotics significantly altered beta diversity of the gut microbiota by day 6, with ceftriaxone exhibiting the most prolonged effects. Changes in the composition of the gut microbiota were more similar between the ceftazidime-avibactam and piperacillin-tazobactam groups, and distinct from those observed in the ceftriaxone group. Consistent with beta diversity changes, bacterial interaction networks revealed greater and longer-lasting disruptions of bacterial interaction in the gut microbiota in the ceftriaxone group compared to the other two antibiotics. These findings highlight distinct patterns of microbiota disruption following ceftriaxone, ceftazidime-avibactam, and piperacillin-tazobactam treatments and underscore the importance of antibiotic selection in minimizing gut dysbiosis.
抗生素的使用会导致肠道微生物群失调，进而引发艰难梭菌感染，并且与肠易激综合征和代谢综合征等疾病有关。然而，不同抗生素对肠道微生物群组成的具体影响仍未得到充分表征，尤其是在人体研究中。先前发表的一项I期研究探讨了结肠靶向吸附剂DAV132在减轻健康个体中抗生素相关失调对肠道微生物群影响方面的作用。利用该出版物PRJNA922086中的公开数据集，我们评估了用两种广谱β-内酰胺/β-内酰胺酶抑制剂抗生素头孢他啶-阿维巴坦、哌拉西林-他唑巴坦以及第三代头孢菌素头孢曲松进行为期5天的静脉治疗，在给药后第1天、第6天和第37天对肠道微生物群的多样性、组成和细菌相互作用的影响。到第6天时，所有三种抗生素均显著改变了肠道微生物群的β多样性，其中头孢曲松的影响最为持久。头孢他啶-阿维巴坦组和哌拉西林-他唑巴坦组肠道微生物群组成的变化更为相似，与头孢曲松组观察到的变化不同。与β多样性变化一致，细菌相互作用网络显示，与其他两种抗生素相比，头孢曲松组肠道微生物群中细菌相互作用的破坏更大且持续时间更长。这些发现突出了头孢曲松、头孢他啶-阿维巴坦和哌拉西林-他唑巴坦治疗后微生物群破坏的不同模式，并强调了选择抗生素以尽量减少肠道失调的重要性。
